The People Building AGI Just Warned Congress It Can Help Make Bioweapons

On June 5, 2026, the chief executives of OpenAI, Anthropic, Google DeepMind, and Microsoft AI signed a joint letter to the United States Congress. They asked for mandatory screening requirements on synthetic DNA providers. Their argument: the AI systems their companies are building have already lowered the expertise threshold for designing biological weapons, and the gap between "AI can help you understand dangerous biology" and "AI can help you build something that kills people" is narrowing faster than biosecurity infrastructure is improving.

When Sam Altman, Dario Amodei, Demis Hassabis, and Mustafa Suleyman sign the same document, it carries unusual weight. These four are the people responsible for building the systems they are warning about.

The Ask: Screen Every DNA Order

The letter, organized by the Foundation for American Innovation and the Institute for Progress, makes a narrow ask. Synthetic DNA vendors (companies that will synthesize custom DNA sequences and mail them to you) should be required to screen every order against databases of known dangerous sequences, verify customer identity, and conduct risk assessments before shipping. Today that screening is voluntary and applied inconsistently.

The underlying claim is that AI has changed the calculus. Designing a dangerous pathogen historically required deep expertise in microbiology, virology, and molecular biology, the kind of knowledge that took years to accumulate and was hard to acquire outside an institution. AI systems that can reason about protein structure, genetic sequences, and pathogen mechanisms lower that barrier. They don't erase the need for expertise, but they compress what used to take months of specialized study into a process that a motivated non-expert can work through with AI assistance.

The letter does not claim that any current AI system can produce a bioweapons blueprint on demand. It claims that the trajectory makes uncontrolled access to synthetic DNA synthesis more dangerous every year, and that the window for preventive action is closing.

Why the Executives Point Downstream

The position these four executives have put themselves in is structurally awkward. The letter's argument runs: our systems make dangerous capabilities more accessible, so please regulate the downstream supply chain to limit the damage. The argument they decline to make, and that nobody is forcing them to make, is that the development of systems with these properties should itself be governed.

The pattern is familiar. The same competitive dynamics that drive capability development also produce a particular flavor of safety advocacy, one focused on mitigating the downstream effects of dangerous capabilities rather than limiting the capabilities themselves. Export controls on chips, screening of DNA vendors, watermarking of AI-generated content: all of these target the periphery while the capabilities keep scaling.

None of this implies bad faith. Amodei in particular has been among the more serious voices on AI risk for years. But the shape of the advocacy is telling. The competitive dynamics that make unilateral restraint individually irrational also shape which safety positions executives are willing to advocate in public.

AI and Dual-Use Biology

The biosecurity concern predates this letter. Yoshua Bengio, in the International AI Safety Report 2026, flagged AI-enabled biological risk as one of the most pressing near-term threats from advanced AI systems. The worry isn't new. The pace is.

AlphaFold, DeepMind's protein structure prediction system, was a real scientific breakthrough that accelerated drug discovery and biological research. It also made it easier to reason about protein function in ways that carry dual-use implications. The same goes for large language models that have absorbed vast amounts of biological literature and can synthesize it on request. The beneficial and harmful applications run on the same underlying capability. You can't deploy "the part that helps with cancer research" while withholding "the part that could inform pathogen enhancement."

Screening the DNA vendors is a sensible downstream control that leaves this underlying dynamic untouched. It is probably worth doing anyway.

The Legislation Already in Motion

The letter isn't arriving into a policy vacuum. In late January 2026, Senators Tom Cotton and Amy Klobuchar introduced the Biosecurity Modernization and Innovation Act (S.3741), which would codify mandatory screening requirements for synthetic biology providers. The joint executive letter looks designed to give that bill industry momentum. Tech-sector support for biosecurity regulation is an unusual alignment, and it could speed passage.

Whether screening DNA orders addresses the actual risk depends on what you think the risk is. If the threat model is "someone uses AI to design a dangerous sequence and then orders the physical DNA to synthesize it," then vendor screening is a meaningful control. If the threat model is "AI provides sufficient technical uplift that non-state actors can build biological threats through pathways that don't require ordered synthesis," then vendor screening is a partial solution to a portion of the problem.

Two Threats, One Bill

The signatories are not naive about what they're building. Amodei's published work on AI safety has been more forthright about existential risk than almost any other lab leader's, and Hassabis came out of DeepMind's safety-conscious research culture. When the four most powerful AI executives in the world jointly warn Congress that their technology creates bioweapons risk, that warning carries weight because of who is making it.

It also sharpens the stakes. For years the risk calculus around advanced AI has been dominated by the alignment problem: what happens if a highly capable system pursues misaligned goals. The biosecurity letter points somewhere else, at what happens when humans use AI capabilities to pursue destructive goals. These two risks call for different responses. Alignment has to be solved on its own terms; misuse demands governance of the AI and the infrastructure around it.

Neither is solved today. Screening synthetic DNA vendors, if it passes, addresses a narrow slice of the misuse problem. The alignment problem is not on any legislative agenda anywhere.